Cefprozil

證據等級: L5

預測適應症: 10 個

Cefprozil: From Respiratory Tract Infections to Urinary Tract Infection

One-Sentence Summary

Cefprozil is an orally active second-generation cephalosporin antibiotic, originally used to treat upper and lower respiratory tract infections and skin/soft tissue infections. The TxGNN model predicts it may be effective for Urinary Tract Infection, with no registered clinical trials but 9 publications (including 3 dedicated RCTs) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Upper/lower respiratory tract infections; skin and soft tissue infections
Predicted New Indication	Urinary Tract Infection
TxGNN Prediction Score	99.99%
Evidence Level	L1
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the DrugBank query. Based on known pharmacological information, Cefprozil is an oral second-generation cephalosporin β-lactam antibiotic. β-lactam drugs inhibit bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), blocking peptidoglycan cross-linking and ultimately causing cell lysis. Cefprozil is particularly active against gram-positive organisms (Streptococcus pyogenes, S. pneumoniae, methicillin-susceptible S. aureus) and has moderate activity against gram-negative pathogens (Haemophilus influenzae, Moraxella catarrhalis, Enterobacteriaceae).

The rationale for UTI is mechanistically straightforward: the most common UTI pathogens — Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis — fall squarely within Cefprozil’s antibacterial spectrum via PBP inhibition. Following oral administration, Cefprozil achieves high urinary concentrations, reaching therapeutic levels that exceed the MICs of susceptible uropathogens. In vitro data from clinical isolates in Taiwan (Liu et al., 1995) confirmed inhibition of >80% of E. coli and Klebsiella at 8 mg/L. This profile is mechanistically consistent with approved second-generation cephalosporins already used in UTI management guidelines.

Crucially, three randomized controlled trials conducted specifically for acute uncomplicated UTIs in the early 1990s demonstrated clinical and bacteriological cure rates of 93–94% with Cefprozil 500 mg once daily — comparable to Cefaclor as the active comparator. These trials provide direct clinical evidence rather than mere inference from spectrum data, elevating the confidence in this prediction to L1.

Clinical Trial Evidence

Currently no related clinical trials registered for Cefprozil in urinary tract infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1761453	1991	RCT	J Antimicrobial Chemotherapy	Open randomized trial in 102 adults: Cefprozil 500 mg QD vs Cefaclor 250 mg TID for 10 days in acute uncomplicated UTI; comparable clinical and bacteriological cure rates
1611652	1992	RCT	Clinical Therapeutics	Multicenter randomized study in patients ≥2 years old: Cefprozil QD vs Cefaclor TID for 10 days; satisfactory clinical response rates comparable between groups
1952874	1991	RCT	Antimicrobial Agents & Chemotherapy	108 college women with acute UTI; Cefprozil 500 mg QD vs Cefaclor 250 mg TID — clinical cure 94% and bacterial cure 93% for Cefprozil, not significantly different from Cefaclor
7681376	1993	Systematic Review	Drugs	Comprehensive review confirming Cefprozil’s broad antibacterial activity including against common UTI pathogens (E. coli, Klebsiella, Enterobacteriaceae); MRSA and some gram-negatives not susceptible
8464648	1993	Drug Review	Pediatric Annals	Overview of Cefprozil’s role in respiratory, skin, and UTI infections; favorable GI and dermatological side effect profile highlighted; once/twice daily dosing feasible
8042575	1994	Comparative Review	American Family Physician	Cefprozil among newer oral cephalosporins positioned as an effective, convenient twice-daily option for skin, respiratory, and urinary tract infections
8529432	1995	In Vitro Study	Chemotherapy	In vitro activity against 637 clinical isolates from Kaohsiung VGH, Taiwan: Cefprozil inhibited >80% of E. coli and Klebsiella pneumoniae at 8 mg/L; comparable to other oral cephalosporins
1494237	1992	Pediatric Clinical Study	Japanese J Antibiotics	PK/PD characterized in children after oral Cefprozil; urinary concentrations and recovery rates measured; relevant for pediatric UTI dosing
1289583	1992	Pediatric Clinical Study	Japanese J Antibiotics	21 children with bacterial infections including 3 UTI cases; good to excellent clinical responses in 19/21 patients; all 11 bacterial strains eradicated

India Market Information

Cefprozil currently has no product registrations in India. No authorization records are available in the CDSCO database.

Safety Considerations

Drug Interactions (55 interactions identified in DDInter database; notable interactions listed below):

Moderate-level interactions:

Interacting Drug	Level	Clinical Note
Kanamycin	Moderate	Concurrent aminoglycoside use may increase nephrotoxicity risk
Neomycin	Moderate	Potential additive renal effects; monitor renal function
Streptomycin	Moderate	Caution with combined aminoglycoside use
Balsalazide	Moderate	Cephalosporins may alter gut microbiome, affecting balsalazide metabolism
Picosulfuric acid	Moderate	Antibiotics may reduce efficacy of gut-acting laxatives

Unknown-level interactions (selected notable agents):

Acetylsalicylic acid, Amoxicillin, Pantoprazole, Omeprazole, Lansoprazole, Cimetidine, Prednisone, Prednisolone, Metformin, Simvastatin — interaction profiles with Cefprozil are not fully characterized in available databases.

For complete warnings and contraindications, please refer to the full package insert.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three dedicated RCTs from the 1990s directly demonstrated Cefprozil’s efficacy in acute uncomplicated UTIs with cure rates of ~93–94%, and the mechanistic basis — broad-spectrum β-lactam PBP inhibition combined with high urinary drug concentrations — is well-established. However, Cefprozil is not currently marketed in India, and the supporting trials are over 30 years old, predating the current era of widespread ESBL and fluoroquinolone-resistant uropathogens.

To proceed, the following is needed:

Current local resistance data: Obtain contemporary antibiogram data for UTI pathogens in India; assess ESBL prevalence and resistance patterns among E. coli and Klebsiella, which may substantially reduce the drug’s clinical utility compared to the 1990s trial data
Regulatory pathway: Initiate CDSCO market authorization application; define the target indication scope (uncomplicated lower UTI only, or broader)
Package insert retrieval: Download and review the full prescribing information for approved warnings, contraindications, and special population guidance (renal dosing adjustments, pregnancy category)
MOA data: Resolve the DrugBank data gap to complete the mechanistic risk assessment
Bridging evidence plan: Consider a locally-relevant PK/PD study or prospective observational study in Indian patients to establish contemporary clinical evidence, particularly given changes in regional pathogen susceptibility profiles since the original registration trials
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.